M Pharmaceutical (CSE:MQ) has welcomed world renowned biotech sector executive, Douglas Janzen, as its senior clinical advisor.
The Vancouver based Janzen has accumulated 20 years of experience in the managing and developing life sciences focused businesses as a co-founder of Northview Ventures, a strategic investment and consulting firm focused on life sciences and high tech, and CEO of Aequus Pharmaceuticals.
Before founding Northview Ventures, Janzen occupied successive senior roles including CFO and then President and CEO atCardiome Pharma, where he raised over C$300 million and completed over C$1 billion in licensing deals.
Janzen also forged a partnership with Merck that brought Cardiome's flagship product "Brinavess" through to clinical approval and marketing in Europe.
Janzen is uniquely qualified to understand the investment dynamics of the biotech sector, having been an investment banker with Cormark Securities, specializing in life sciences before taking on sector leadership roles. He has completed over $1 billion in equity financing for Canadian bio-tech companies and has previously served as chair of LifeSciences BC and as a director with Biotech Canada.
"With his leadership reputation in biotechnology, pharma and life sciences and an impressive toolkit in the areas of entrepreneurship, finance and business development, Douglas is bound to deliver significant added value to everything we do in bringing our own innovative biomedical technologies to market." said M Pharma’s President and CEO, Dr. Martin Mintchev.
Janzen serves on the boards of Neovasc, Aequus, Alabaster Technologies, Ico Therapeutics, Perimeter Medical Imaging, Renaissance Biosciences and Synaptive Technologies.
M Pharma is pursuing an ambitious brand development strategy as it builds on a successful round of biotech acquisitions focused on the treatment of diabetes and obesity.
Over the past three months, M Pharmaceutical Inc. has acquired three biomedical technologies addressing obesity and diabetes in a less invasive manner than its market competitors. This process started with M Diagnostics, as announced last February 19, which held the right to eMosquito.